These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36150309)

  • 21. Emerging Trends of Nanomedicines in the Management of Prostate Cancer: Perspectives and Potential Applications.
    Deshmukh R; Singh V; Harwansh RK; Agrawal R; Garg A; Singh S; Elossaily GM; Ansari MN; Ali N; Prajapati BG
    Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GRP78-targeted and doxorubicin-loaded nanodroplets combined with ultrasound: a potential novel theranostics for castration-resistant prostate cancer.
    Zhao Y; Shi D; Shang M; Sun X; Guo L; Meng D; Liu X; Zhou X; Li J
    Drug Deliv; 2022 Dec; 29(1):203-213. PubMed ID: 34985396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferroptosis and ferroptosis-inducing nanomedicine as a promising weapon in combination therapy of prostate cancer.
    Huang M; Teng Q; Cao F; Huang J; Pang J
    Biomater Sci; 2024 Mar; 12(7):1617-1629. PubMed ID: 38379396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.
    Andrew J; Ezra-Manicum AL; Witika BA
    EJNMMI Radiopharm Chem; 2024 Aug; 9(1):62. PubMed ID: 39180599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials.
    Xu M; Han X; Xiong H; Gao Y; Xu B; Zhu G; Li J
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review.
    Upadhyay TK; Ali MI; Khan F; Goel H; Mathur M; Goyal K; Moin S; Pandey P; Tanwar P; Sharangi AB; Gautam SDC; Kapdi JK; Patel KI; Patel MV; Parmar AM; Kamal MA
    Curr Med Chem; 2022; 29(24):4170-4184. PubMed ID: 34939536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine for urologic cancers: diagnosis and management.
    Li C; Zeng X; Qiu S; Gu Y; Zhang Y
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):463-475. PubMed ID: 35660001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
    Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
    Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.
    Chakraborty K; Tripathi A; Mishra S; Mallick AM; Roy RS
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35638450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bridging Bio-Nano Science and Cancer Nanomedicine.
    Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
    ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
    Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.